PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 323.50
Bid: 325.00
Ask: 328.50
Change: -7.50 (-2.27%)
Spread: 3.50 (1.077%)
Open: 329.00
High: 332.00
Low: 320.00
Prev. Close: 331.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PDMR Dealings

14 Oct 2022 14:28

RNS Number : 9897C
Oxford Biomedica PLC
14 October 2022
 

 

 

 

PDMR Dealings

 

Oxford, UK - 14 October 2022: Oxford Biomedica plc ("Oxford Biomedica" or "the Company") (LSE:OXB), a leading gene and cell therapy group, was informed today, that Dr. James Miskin, Chief Technical Officer, exercised 19,540 LTIP (2017), 7,357 LTIP (2018) and 14,192 (2019) options at nil cost on 13 October 2022. All of the resulting 41,089 ordinary shares were sold at 320p per share on 13 October 2022. Following this transaction Dr. James Miskin holds options over 140,268 ordinary shares.

 

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of ordinary shares exercised and then sold.

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")

a)

Name

James Miskin

2.

Reason for the notification

a)

Position/status

Chief Technical Officer

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Options over ordinary shares of 50 pence each

 

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Exercise of options

c)

Currency

GBP - British pound

d)

Price(s) and volumes(s)

 

Price(s)

Volume(s)

Nil

41,089

e)

Aggregated information

- Aggregate volume

- Aggregate price

- Aggregated total

 

41,089

 

Nil

 

Nil

f)

Date of the transaction

2022-10-13

g)

Place of the transaction

Outside a trading venue

 

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")

a)

Name

James Miskin

2.

Reason for the notification

a)

Position/status

Chief Technical Officer

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Oxford Biomedica plc

b)

LEI code

213800S1GVQNXQ15K851

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary shares of 50 pence each

 

 

ISIN: GB00BDFBVT43

b)

Nature of the transaction

Sale of ordinary shares

c)

Currency

GBP - British pound

d)

Price(s) and volumes(s)

 

Price(s)

Volume(s)

£3.20

 41,089

e)

Aggregated information

- Aggregate volume

- Aggregated price

- Aggregated total

 

41,089

 

£3.20

 

£131,484.80

f)

Date of the transaction

2022-10-13

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 

-Ends-

 

For further information, please contact:

 

Oxford Biomedica plc:

Natalie Walter, Company Secretary

 

Tel: +44 (0)1865 783 000

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral vector delivery systems including those based on lentivirus, adeno-associated virus (AAV) and adenovirus, providing innovative solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. Oxford Biomedica has built a sector leading lentiviral vector delivery system, LentiVector® platform, and is working on programmes from pre-clinical to commercial stage across a range of therapeutic areas with global partners.

 

Oxford Biomedica is based across several locations and headquartered in Oxfordshire, UK. In 2022, the Group established Oxford Biomedica Solutions, a US based subsidiary AAV manufacturing and innovation business, based near Boston, US.

 

Further information is available at www.oxb.com.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFFMFDLEESEES
Date   Source Headline
23rd Oct 202010:27 amRNSDirector Purchase
12th Oct 20205:38 pmRNSHolding(s) in Company
6th Oct 202012:46 pmRNSAxovant update on 2nd cohort of SUNRISE-PD trial
6th Oct 20207:00 amRNSOXB receives approval for fourth suite in Oxbox
5th Oct 202010:59 amEQSEdison Investment Research Limited: Oxford Biomedica (OXB): Vector innovation key to cell and gene evolution
2nd Oct 202011:52 amRNSTotal Voting Rights
29th Sep 20203:51 pmRNSDirector Dealings
24th Sep 20209:36 amRNSDirector/PDMR Shareholding
22nd Sep 202012:54 pmRNSDirector/PDMR Shareholding
17th Sep 20207:00 amRNSInterim Results
1st Sep 20209:33 amRNSTotal Voting Rights
1st Sep 20207:00 amRNSMaster Supply and Development Agreement with AZ
27th Aug 20207:00 amRNSNotice of Interim Results
25th Aug 20204:46 pmRNSBlock listing Application
3rd Aug 20209:41 amRNSTotal Voting Rights
3rd Aug 20207:00 amRNSOXB signs DMLA with Beam Therapeutics
31st Jul 20207:00 amRNSOXB Signs Clinical Supply Agreement with Axovant
20th Jul 20204:23 pmRNSOXB notes interim results from AZ on AZD1222
3rd Jul 202010:45 amRNSDirector Dealings / Market Share Purchase
2nd Jul 20203:39 pmRNSDirector Dealings / Market Share Purchase
2nd Jul 20201:34 pmRNSDirector Dealings / Market Share Transactions
1st Jul 20206:30 pmRNSHoldings in Company
1st Jul 20203:44 pmRNSBlock listing Return
1st Jul 20209:13 amRNSTotal Voting Rights
30th Jun 20203:23 pmRNSGrant of options
25th Jun 20209:44 amRNSHolding(s) in Company
24th Jun 202011:45 amRNSHoldings in Company
24th Jun 20209:54 amRNSDirector Dealings / Share Disposal – Replacement
24th Jun 20207:00 amRNSDirector Dealings / Market Share Purchase
23rd Jun 20204:46 pmRNSResult of Annual General Meeting
23rd Jun 20202:47 pmRNSAdmission of shares and Total Voting Rights.
23rd Jun 20207:00 amRNSAnnual General Meeting
19th Jun 20203:26 pmRNSInformation in Relation to Annual General Meeting
19th Jun 20207:00 amRNSResult of Placing
18th Jun 20205:33 pmRNSProposed Placing of new Ordinary Shares
8th Jun 20204:01 pmRNSUpdate on Sanofi Ophthalmology Programmes
8th Jun 20207:00 amRNSFive Year Collaboration Agreement signed with VMIC
1st Jun 20209:06 amRNSTotal Voting Rights
1st Jun 20207:00 amRNSDr Roch Doliveux appointed Non-Executive Chairman
28th May 202012:16 pmRNSClinical & Commercial Supply Agreement with AZ
27th May 202011:26 amRNSDirector Dealings / Market Share Purchase
22nd May 20205:28 pmRNS2019 Annual report and Accounts & AGM Notification
20th May 20202:34 pmRNSHolding(s) in Company
13th May 20206:02 pmRNSHolding(s) in Company
13th May 20207:00 amRNSOXB receives approval for first two Oxbox suites
11th May 20204:25 pmRNSPDMR Dealings / Market Share sale
6th May 202012:36 pmRNSDirectors Dealings / Market Share Purchases
6th May 20207:00 amRNSPreliminary Results
1st May 20209:05 amRNSTotal Voting Rights
28th Apr 20201:04 pmRNSCompliance with LR 9.2.6ER(1)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.